Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 10:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–262 of 262 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Disorder of Endocrine Ovary Clear all
Withdrawn Not applicable Interventional Accepts healthy volunteers

Plant Exosomes and Patients Diagnosed With Polycystic Ovary Syndrome (PCOS) 17

NCT03493984
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Ginger exosomes, Aloe exosomes, Placebo
Other
Lead sponsor
University of Louisville
Other
Eligibility
18 Years to 40 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Mar 16, 2021 · Synced Oct 23, 2026, 10:15 AM EDT
Completed No phase listed Observational

PCOS Twin Study - Environmental Factors in the Development of Polycystic Ovary Syndrome, Phase 2

NCT00444288
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
Not listed
Lead sponsor
National Institute of Environmental Health Sciences (NIEHS)
NIH
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 23, 2026, 10:15 AM EDT
Terminated Phase 1 Interventional

A Study of SGN-MesoC2 in Advanced Solid Tumors

NCT06466187
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Adenocarcinoma, Colorectal Neoplasms, Mesothelioma, Other Solid Tumors, Endometrial
Interventions
PF-08052666
Drug
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
16
States / cities
Birmingham, Alabama • Fairway, Kansas • Kansas City, Kansas + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 23, 2026, 10:15 AM EDT
Completed Phase 1 Interventional Results available

Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies

NCT00496860
View directory record Official record
Conditions
Progressive Metastatic Malignancies
Interventions
ALT-801
Biological
Lead sponsor
Altor BioScience
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
4
States / cities
Aurora, Colorado • Orlando, Florida • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 22, 2013 · Synced Oct 23, 2026, 10:15 AM EDT
Terminated Phase 1Phase 2 Interventional Results available

Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors

NCT05194735
View directory record Official record
Conditions
Gynecologic Cancer, Colorectal Cancer, Pancreatic Cancer, Non-small Cell Lung Cancer, Cholangiocarcinoma, Ovarian Cancer, Endometrial Cancer, Ovarian Carcinoma, Ovary Neoplasm, Squamous Cell Lung Cancer, Adenocarcinoma of Lung, Adenosquamous Cell Lung Cancer
Interventions
Neoantigen specific TCR-T cell drug product, Aldesleukin (IL-2)
Biological
Lead sponsor
Alaunos Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 23, 2026, 10:15 AM EDT
Terminated Phase 2 Interventional

Weekly Topotecan Therapy in Patients With Ovarian Cancer

NCT00194935
View directory record Official record
Conditions
Ovarian Cancer
Interventions
Topotecan
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 13, 2006 · Synced Oct 23, 2026, 10:15 AM EDT
Recruiting Phase 1 Interventional

Study of NTB-928 in R/R OC

NCT07690189
View directory record Official record
Conditions
Relapsed/Refractory Ovarian Carcinoma
Interventions
NTB-928
Drug
Lead sponsor
TeneoSeven, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
Birmingham, Alabama • Omaha, Nebraska • Lake Success, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 23, 2026, 10:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Study of Insulin Resistance and Endometrial Cancer in Harris County, Texas

NCT00495235
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Questionnaire
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
147 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
8
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Oct 23, 2026, 10:15 AM EDT
Active, not recruiting Not applicable Interventional

Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)

NCT05743517
View directory record Official record
Conditions
Ovary Cancer, Endometrial Cancer, Uterine Cancer, Cervical Cancer, Cervix Cancer, Vulvar Cancer, Vaginal Cancer
Interventions
Fit4Treatment
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
60 Years and older · Female only
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 23, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Results available

Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer

NCT00327171
View directory record Official record
Conditions
Neoplasms, Cancer of the Ovary
Interventions
Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older · Female only
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 7, 2016 · Synced Oct 23, 2026, 10:15 AM EDT
Withdrawn Early Phase 1 Interventional

Effect of Short Term Adrenal Suppression on Androgen Overproduction in Overweight Girls With Androgen Excess

NCT01422707
View directory record Official record
Conditions
Hyperandrogenemia, Obesity, Polycystic Ovary Syndrome
Interventions
Hydrocortisone
Drug
Lead sponsor
University of Virginia
Other
Eligibility
7 Years to 18 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 19, 2018 · Synced Oct 23, 2026, 10:15 AM EDT
Active, not recruiting Phase 4 Interventional Results available

Randomized Controlled Trial of Combined Letrozole and Clomid (CLC II) Versus Letrozole Alone for Women With Anovulation

NCT05206448
View directory record Official record
Conditions
Polycystic Ovary Syndrome, PCOS, Infertility
Interventions
Letrozole, Clomiphene Citrate
Drug
Lead sponsor
Rachel Mejia
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
4
States / cities
Davenport, Iowa • Iowa City, Iowa • West Des Moines, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Oct 23, 2026, 10:15 AM EDT
Completed No phase listed Observational

Radiotherapy Assessments During Intervention ANd Treatment (RADIANT)

NCT03133286
View directory record Official record
Conditions
Radiation Therapy, Cancer, Cancer of Anus, Cancer of Bladder, Cancer of Cervix, Cancer of Colon, Cancer of Rectum, Cancer of Esophagus, Cancer of Gallbladder, Cancer of Liver, Cancer of Ovary, Cancer of Pancreas, Cancer of Prostate, Cancer of Kidney and Renal Pelvis, Cancer of Stomach, Cancer of Testis, Cancer of Uterus, Cancer of Uterus and Cervix, Cancer of Kidney
Interventions
Not listed
Lead sponsor
DxTerity Diagnostics
Industry
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
4
States / cities
Compton, California • Bradenton, Florida • Fort Myers, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 7, 2024 · Synced Oct 23, 2026, 10:15 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines

NCT02432378
View directory record Official record
Conditions
Cancer of Ovary, Cancer of the Ovary, Neoplasms, Ovarian, Ovarian Cancer, Ovary Cancer, Ovary Neoplasms
Interventions
Cisplatin + celecoxib + DC vaccine, Cisplatin + CKM + Celecoxib + DC Vaccine
Biological
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
2
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 23, 2026, 10:15 AM EDT
Terminated Phase 4 Interventional Results available

Metformin for Ectopic Fat Deposition and Metabolic Markers in Polycystic Ovary Syndrome (PCOS)

NCT02500147
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Non-Alcoholic Fatty Liver Disease, Metabolic Syndrome
Interventions
Metformin, Placebo
Drug
Lead sponsor
Columbia University
Other
Eligibility
13 Years to 25 Years · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 2, 2025 · Synced Oct 23, 2026, 10:15 AM EDT
Not listed Not applicable Interventional

Effect of Spironolactone on Adrenal or Ovarian Androgen Production in Overweight Pubertal Girls With Androgen Excess

NCT01422759
View directory record Official record
Conditions
Obesity, Hyperandrogenemia, Polycystic Ovary Syndrome
Interventions
Spironolactone
Drug
Lead sponsor
University of Virginia
Other
Eligibility
7 Years to 18 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 27, 2023 · Synced Oct 23, 2026, 10:15 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Mechanisms of Increased Androgen Production Among Women With Polycystic Ovary Syndrome

NCT00989781
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
3-D Ultrasound, recombinant human chorionic gonadotropin, Recombinant human follicle stimulating hormone, Adrenocorticotropin, Dexamethasone, Glucose
Radiation · Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 37 Years · Female only
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 4, 2018 · Synced Oct 23, 2026, 10:15 AM EDT
Completed Phase 3 Interventional Results available

Pregnancy in Polycystic Ovary Syndrome II

NCT00719186
View directory record Official record
Conditions
Pregnancy, Polycystic Ovary Syndrome
Interventions
Clomiphene citrate, Letrozole
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
12
States / cities
Birmingham, Alabama • Stanford, California • Aurora, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Oct 23, 2026, 10:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Post-Prandial Liver Glucose Metabolism in PCOS

NCT03041129
View directory record Official record
Conditions
Polycystic Ovarian Syndrome, Obesity, Hepatic Steatosis
Interventions
oral glucose tolerance test, MRI of liver
Diagnostic Test
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 21 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced Oct 23, 2026, 10:15 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Ovarian Ultrasonography for the Clinical Evaluation of Polycystic Ovary Syndrome

NCT03547453
View directory record Official record
Conditions
Polycystic Ovary Syndrome (PCOS), Menstrual Irregularity, Overweight and Obesity
Interventions
Not listed
Lead sponsor
Cornell University
Other
Eligibility
18 Years and older · Female only
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2022
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2023 · Synced Oct 23, 2026, 10:15 AM EDT
Completed Early Phase 1 Interventional

PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer

NCT04041128
View directory record Official record
Conditions
Ovarian Cancer, Breast Cancer
Interventions
Lynparza
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 20, 2023 · Synced Oct 23, 2026, 10:15 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Study of AZD4901 in Females With Polycystic Ovary Syndrome

NCT01872078
View directory record Official record
Conditions
Polycystic Ovary Syndrome (PCOS), Female Endocrine Disorder
Interventions
AZD4901 (oral), Placebo to match AZD4901
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Springfield, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 23, 2026, 10:15 AM EDT